MDM4 expression in wtTP53-tumors is actually a potential indication forTP53reactivation cancer therapy by simultaneous focusing on ofMDM4andMDM2

MDM4 expression in wtTP53-tumors is actually a potential indication forTP53reactivation cancer therapy by simultaneous focusing on ofMDM4andMDM2. restoration, and senescence [1-4]. Approximately half of human cancers have mutations in theTP53gene [5], indicating thatTP53inactivation is pivotal in cancer development. The remaining cancers retain the wild-type (wt) status ofTP53, which is inhibited by deregulated upstream modulators and/or inactivation of downstream effectors [1, 6]. The human homolog of murine double minute 2 (MDM2) is a major negative regulator of p53 through binding to its transactivation domain name, thereby resulting in subsequent suppression of transcriptional activity [7, 8]. In addition , CID 1375606 the RING (Really Interesting New Gene) finger domain of MDM2 functions as an E3 ubiquitin ligase that mediates ubiquitin-dependent degradation of p53 [9-11]. MDM2is a transcriptional target of p53, forming an autoregulatory feedback loop [12, 13]. TP53is also negatively regulated by MDM4, an MDM2 homologue [14, 15]. Like MDM2, MDM4 represses p53 transcriptional activity by direct binding of its binding domain, which is located in the N-terminal region, to the transactivation domain of p53 [14]. Although MDM4 include a RING finger domain, it lacks E3 ligase Goserelin Acetate activity and is unable to directly decrease p53 stability [14], but rather enhances the E3 ligase activity toward p53 by forming a heterodimer with MDM2 via the RING domains of both molecules [16, 17]. MDM2 also destabilizes the structure of MDM4 via ubiquitination [18]. BothMDM2andMDM4function as oncogenes and their deregulated expression continues to be reported in various types of human cancers, including soft tissue sarcoma, breast cancer, retinoblastoma, and melanoma [19-23]. However , currently, the expression patterns and functional roles ofMDM2andMDM4in cancer cells with or withoutTP53mutations remain uncertain. Repair of wtTP53function in tumors leads to quick tumor regression by induction of apoptosis or senescence and can be relevant to cancer treatment [19]. A number of small molecular inhibitors from the interactions between MDM2 and p53 have been shown to restoreTP53activity in tumors expressing large MDM2 levels [24-26]. Similarly, MDM4 antagonists have been reported. Among them, SAH-p53-8 binds and inhibits more efficiently to MDM4 than to MDM2 and exerts antitumor effects in cancer cells expressing high MDM4 levels [21, 27]. Synthetic small interfering CID 1375606 RNAs (siRNAs) are not only a powerful device for functional gene analysis [28, 29], but has been intensively explored to get application to therapy of human cancer and other diseases with some encouraging results [30-32]. siRNAs often silence the expression of untargeted genes with partial sequence complementarities (off-target effects) [33, 34]. However , such nonspecific effects can be avoided by DNA alternative in the seed region from the guide strand (first 68 bases from the 5 end) and the complementary sequences from the passenger strand, which has been specified as a double-stranded RNADNA chimera (dsRDC) [35]. Considering the recent progress in RNAi technology, synthetic siRNAs targetingMDM2andMDM4may present an alternative mechanism to induceTP53restoration. In the present study, we carefully analyzed MDM2 and MDM4 manifestation levels in various cancer cell lines with and withoutTP53mutations and found that MDM2 and MDM4 were deregulated in all wtTP53cancer cells. To probe the roles ofMDM2andMDM4inTP53regulation in cancer cells, we selected efficient and specific dsRDC-modified siRNAs targetingMDM2andMDM4. Individual and combined knockdown ofMDM2andMDM4revealed their roles inTP53inactivation in wtTP53cancer cells with different patterns of MDM2 and MDM4 manifestation, which offered us with a rationale to get the selection ofMDM2andMDM4as targets inTP53restoration therapy of cancers. == RESULTS == == Manifestation levels of MDM2 and MDM4 in cancer cell lines == We examined the expression levels of MDM2 and MDM4 in CID 1375606 14 cancer cell lines including 11 wtTP53and three mutant (mt)TP53cell lines by immunoblotting (Figure1). wtTP53cell lines were divided into two groups in accordance to levels of MDM4: seven cell lines (MCF-7, A375, SNU-1, HCT116, NUGC-4, LoVo, and A549) expressed large levels of MDM4, whereas the remaining four cell lines (SJSA-1, HepG2, HuH-6, and C32TG) expressed low levels of MDM4. Interestingly, almost all cell lines expressing low MDM4 levels accumulated higher levels of MDM2 than those expressing high MDM4 levels. Cell lines transporting mtTP53(KATOIII, NUGC-3, and DLD-1) expressed various levels of MDM4 and MDM2. p53 was not detected in KATOIII cells, which harbored gross deletions of bothTP53alleles. == Number 1 . Manifestation levels of p53, MDM2, and MDM4 in cancer cell lines. == Expression levels of p53, MDM2, and MDM4 were analyzed in 14 cancer cell lines (11 wtTP53cell lines and several mtTP53cell lines) by immunoblotting. SE, short exposure; LE, long direct exposure. == Effective siRNAs focusing on MDM2 and their DNA-modified forms == Seventeen new siRNAs targeting humanMDM2transcript variant 1 .